WO2000015203A3 - Use of methoxymorpholino doxorubicin for the treatment of a liver tumor - Google Patents

Use of methoxymorpholino doxorubicin for the treatment of a liver tumor Download PDF

Info

Publication number
WO2000015203A3
WO2000015203A3 PCT/EP1999/006298 EP9906298W WO0015203A3 WO 2000015203 A3 WO2000015203 A3 WO 2000015203A3 EP 9906298 W EP9906298 W EP 9906298W WO 0015203 A3 WO0015203 A3 WO 0015203A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
liver tumor
methoxymorpholino doxorubicin
methoxymorpholino
doxorubicin
Prior art date
Application number
PCT/EP1999/006298
Other languages
French (fr)
Other versions
WO2000015203A2 (en
Inventor
Maria Adele Pacciarini
Olga Valota
David Kerr
Original Assignee
Pharmacia & Upjohn Spa
Maria Adele Pacciarini
Olga Valota
David Kerr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL14164599A priority Critical patent/IL141645A0/en
Priority to JP2000569787A priority patent/JP5529360B2/en
Application filed by Pharmacia & Upjohn Spa, Maria Adele Pacciarini, Olga Valota, David Kerr filed Critical Pharmacia & Upjohn Spa
Priority to CA002343120A priority patent/CA2343120C/en
Priority to DK99944533T priority patent/DK1112066T3/en
Priority to SI9930349T priority patent/SI1112066T1/en
Priority to EP99944533A priority patent/EP1112066B1/en
Priority to BR9913627-9A priority patent/BR9913627A/en
Priority to HU0103557A priority patent/HU229186B1/en
Priority to DE69909636T priority patent/DE69909636T2/en
Priority to PL348749A priority patent/PL198025B1/en
Priority to AT99944533T priority patent/ATE245029T1/en
Priority to NZ510445A priority patent/NZ510445A/en
Priority to EA200100353A priority patent/EA004570B1/en
Priority to UA2001042524A priority patent/UA69423C2/en
Priority to AU57421/99A priority patent/AU773451B2/en
Publication of WO2000015203A2 publication Critical patent/WO2000015203A2/en
Publication of WO2000015203A3 publication Critical patent/WO2000015203A3/en
Priority to IL141645A priority patent/IL141645A/en
Priority to NO20011116A priority patent/NO329746B1/en
Priority to HK03103135A priority patent/HK1050853A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of methoxymorpholino doxorubicin for the treatment of a liver cancer; in particular, it refers to the intrahepatic administration of methoxymorpholino doxorubicin for use in the liver tumor therapy optionally in association with an agent which remains selectively in liver tumor after its injection through the hepatic artery.
PCT/EP1999/006298 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor WO2000015203A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AT99944533T ATE245029T1 (en) 1998-09-14 1999-08-27 USE OF METHOXYMORPHOLINO DOXORUBICIN TO TREAT A LIVER TUMOR
PL348749A PL198025B1 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
NZ510445A NZ510445A (en) 1998-09-14 1999-08-27 A method for intrahepatic administration of methoxymorpholino doxorubicin (MMDX) to achieve a high concentration at a hepatic tumour site
JP2000569787A JP5529360B2 (en) 1998-09-14 1999-08-27 Use of anthracycline derivatives in the treatment of liver tumors
SI9930349T SI1112066T1 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
EP99944533A EP1112066B1 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
BR9913627-9A BR9913627A (en) 1998-09-14 1999-08-27 Use of an anthracycline derivative for the treatment of a liver tumor
HU0103557A HU229186B1 (en) 1998-09-14 1999-08-27 Use of an anthracycline derivative for the treatment of a liver tumor
DE69909636T DE69909636T2 (en) 1998-09-14 1999-08-27 USE OF METHOXYMORPHOLINO DOXORUBICIN FOR TREATING A LIVER TUMOR
IL14164599A IL141645A0 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
DK99944533T DK1112066T3 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
CA002343120A CA2343120C (en) 1998-09-14 1999-08-27 Use of an anthracycline derivative for the treatment of a liver tumor
EA200100353A EA004570B1 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
UA2001042524A UA69423C2 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin selectively injected through hepatic artery for treatment of liver cancer (variants)
AU57421/99A AU773451B2 (en) 1998-09-14 1999-08-27 Use of an anthracycline derivative for the treatment of a liver tumor
IL141645A IL141645A (en) 1998-09-14 2001-02-26 Pharmaceutical compositions comprising 3'-desamino-3'-(2-methoxymorpholino)doxorubicin for the treatment of a liver tumor
NO20011116A NO329746B1 (en) 1998-09-14 2001-03-05 Use of methoxymorpholinodoxorubicin for the treatment of liver tumor and a pharmaceutical composition containing it
HK03103135A HK1050853A1 (en) 1998-09-14 2003-05-02 se of methoxymorpholino doxorubicin in the preparation of a medicament for the treatment of a liver tumor.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9820012.4 1998-09-14
GBGB9820012.4A GB9820012D0 (en) 1998-09-14 1998-09-14 Use of an anthracycline derivative for the treatment of a liver tumor

Publications (2)

Publication Number Publication Date
WO2000015203A2 WO2000015203A2 (en) 2000-03-23
WO2000015203A3 true WO2000015203A3 (en) 2000-07-20

Family

ID=10838847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006298 WO2000015203A2 (en) 1998-09-14 1999-08-27 Use of methoxymorpholino doxorubicin for the treatment of a liver tumor

Country Status (26)

Country Link
EP (1) EP1112066B1 (en)
JP (2) JP5529360B2 (en)
KR (1) KR100685155B1 (en)
CN (1) CN1168452C (en)
AT (1) ATE245029T1 (en)
AU (1) AU773451B2 (en)
BR (1) BR9913627A (en)
CA (1) CA2343120C (en)
CZ (1) CZ295901B6 (en)
DE (1) DE69909636T2 (en)
DK (1) DK1112066T3 (en)
EA (1) EA004570B1 (en)
ES (1) ES2203175T3 (en)
GB (1) GB9820012D0 (en)
HK (1) HK1050853A1 (en)
HU (1) HU229186B1 (en)
ID (1) ID28035A (en)
IL (2) IL141645A0 (en)
MY (1) MY124247A (en)
NO (1) NO329746B1 (en)
NZ (1) NZ510445A (en)
PL (1) PL198025B1 (en)
PT (1) PT1112066E (en)
TW (1) TWI222868B (en)
UA (1) UA69423C2 (en)
WO (1) WO2000015203A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
WO2004038404A2 (en) * 2002-10-28 2004-05-06 Pharmacia Italia Spa Method for optimizing therapeutic efficacy of nemorubicin
US20060264388A1 (en) * 2003-02-26 2006-11-23 Olga Valota Method for treating liver cancer by intrahepatic administration of nemorubicin
US8940334B2 (en) 2007-05-11 2015-01-27 Nerviano Medical Sciences S.R.L. Pharmaceutical composition of an anthracycline
JP2016124818A (en) * 2014-12-26 2016-07-11 日本化薬株式会社 Metastatic liver cancer treatment drug and metastatic liver cancer treatment method
PL244818B1 (en) * 2021-11-03 2024-03-11 Urteste Spolka Z Ograniczona Odpowiedzialnoscia Compound - a diagnostic marker for liver cancer, method for detecting enzyme activity, method for diagnosing liver cancer, kit comprising such a compound and uses of such a compound and method for treating liver cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BAKKER, M. ET AL: "Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients", BRITISH JOURNAL OF CANCER, vol. 77, no. 1, January 1998 (1998-01-01), pages 139 - 146, XP000893190 *
CARR, B.I. ET AL: "Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepaocellular carcinoma: Interim analysis", SEMINARS IN ONCOLGY, vol. 24, no. 2 suppl. 6, April 1997 (1997-04-01), pages S6-97 - S6-99, XP000893102 *
CARR, B.I. ET AL: "Prolonged survival with chemotherapy alone for hepatocellular carcinoma (HCC) with intra-arterial chemotherapy", PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 13, March 1994 (1994-03-01), pages 205, XP000893111 *
KIRK, S. ET AL: "Irresectable hepatoma treated by intrahepatic iodized oil doxorubicin hydrochloride: Initial results", SURGERY, vol. 109, no. 6, 1991, pages 694 - 697, XP000893192 *
QUINTIERI, L. ET AL: "Delivery of methoxymorpholinyl doxorubicn by interleukin 2-activated NK cells: Effect in mice bearing hepatic metastases", BRITISH JOURNAL OF CANCER, vol. 79, no. 7-8, March 1999 (1999-03-01), pages 1067 - 1073, XP000893191 *
ROBERT, J. ET AL: "Pharmacokinetics and metabolism of anthracyclines", CANCER SURVEYS, vol. 17, 1993, pages 219 - 252, XP000893095 *
ROUGIER, P. ET AL: "Intérêt des chimiothérapies loco-régionales par les anthracyclines", PATHOLOGIE BIOLOGIE, vol. 35, no. 1, 1987, pages 123 - 128, XP000893118 *
TAUB, R.N. ET AL: "Phase II study of methoxymorpholinodoxorubicin in advanced sarcomas (PNU/S2243 (FCE 23762))", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 16, 1997, pages A1831, XP002135896 *
VASEY, P.A. ET AL: "Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762)", CANCER RESEARCH, vol. 55, no. 10, 1995, pages 2090 - 2096, XP000891501 *

Also Published As

Publication number Publication date
EA200100353A1 (en) 2001-10-22
GB9820012D0 (en) 1998-11-04
MY124247A (en) 2006-06-30
EP1112066A2 (en) 2001-07-04
TWI222868B (en) 2004-11-01
NO329746B1 (en) 2010-12-13
DE69909636T2 (en) 2004-06-09
NO20011116D0 (en) 2001-03-05
HUP0103557A2 (en) 2002-01-28
KR100685155B1 (en) 2007-02-22
NZ510445A (en) 2003-01-31
PL198025B1 (en) 2008-05-30
KR20010075074A (en) 2001-08-09
DE69909636D1 (en) 2003-08-21
IL141645A0 (en) 2002-03-10
CN1168452C (en) 2004-09-29
NO20011116L (en) 2001-05-14
AU773451B2 (en) 2004-05-27
PT1112066E (en) 2003-11-28
CA2343120C (en) 2009-11-24
ATE245029T1 (en) 2003-08-15
UA69423C2 (en) 2004-09-15
CZ295901B6 (en) 2005-11-16
IL141645A (en) 2007-05-15
CA2343120A1 (en) 2000-03-23
JP2002524496A (en) 2002-08-06
ES2203175T3 (en) 2004-04-01
JP2014088398A (en) 2014-05-15
EP1112066B1 (en) 2003-07-16
BR9913627A (en) 2001-05-22
WO2000015203A2 (en) 2000-03-23
DK1112066T3 (en) 2003-11-03
EA004570B1 (en) 2004-06-24
HK1050853A1 (en) 2003-07-11
ID28035A (en) 2001-05-03
JP5529360B2 (en) 2014-06-25
CZ2001895A3 (en) 2001-08-15
HUP0103557A3 (en) 2002-12-28
PL348749A1 (en) 2002-06-03
CN1383382A (en) 2002-12-04
HU229186B1 (en) 2013-09-30
AU5742199A (en) 2000-04-03

Similar Documents

Publication Publication Date Title
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
WO2006046080A8 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
IT1309583B1 (en) PERFECTED CATHETER FOR VASCULAR INTERVENTIONS.
WO2004110390A3 (en) Anti-cd74 immunoconjugates and methods
WO2002029103A3 (en) Gene expression profiles in liver cancer
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001282717A1 (en) Cancer treatment by combination therapy
WO2007047291A3 (en) Anti-glypican-3 antibody
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003072754A3 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2000066093A3 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
WO2002027315A3 (en) Compounds with a branched linker
WO2000015203A3 (en) Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
WO2000013712A3 (en) Methods and compositions for the prevention or treatment of cancer
WO2002051388A3 (en) Treatment of inoperable tumors by stereotactic injection of microspheres
BR0014192A (en) Dye and antibody conjugates against angiogenesis target structures for intraoperative representation of tumor margin
EP1234585A3 (en) Methods and compositions for the prevention or treatment of cancer
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO1999064065A3 (en) Tumour therapy and imaging
AU2001296224A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2003020371A3 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99810911.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 57421/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 569787

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2343120

Country of ref document: CA

Ref document number: 2343120

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 510445

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV2001-895

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/002627

Country of ref document: MX

Ref document number: 1020017003222

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999944533

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200100353

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 09786998

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999944533

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017003222

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-895

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1999944533

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 57421/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: PV2001-895

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1020017003222

Country of ref document: KR